Therefore, this suggests a new strategy for the future treatment of colorectal cancer: through the complementary mechanism of dual inhibitors, block the inhibition of CTLA-4 on T cell activation in the early stage and PD-1 on T cell anti-tumor response in the later stage, improve the immune response and promote the anti-tumor immune response (44). This evidence concerns the gene CTLA4 and colorectal cancer.